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A B S T R A C T
Several trials have proposed ACE-inhibitors as the foundation of anti-ischemic sec-
ondary preventive therapy for both short and long-term benefit in systolic heart failure, 
and an important anti-ischemic therapy in ischemic heart disease, diabetic and renal 
disease patients. The results of the HOPE trial indicated that ramipril, with “tissue” 
ACE-inhibition features, would benefit a broad range of patients for both primary 
and secondary prevention of both ischemic and vascular disease, and was beneficial 
in all subgroups of atherosclerotic coronary disease, cerebrovascular disease, periph-
eral vascular disease, or diabetes with one cardiovascular risk factor. Subsequently, 
the EUROPA trial complemented the findings of the HOPE trial in indicating the 
unique ability of tissue ACE-inhibition, this time with use of perindopril, in prevent-
ing cardiovascular events. On the other hand, the findings of a third trial (PEACE) 
using trandolapril did not confirm these favorable effects, albeit in a lower risk group 
of patients with ischemic heart disease. Nevertheless, combined analysis of the results 
of all three trials indicated that there seems to be a significant reduction of cardiovas-
cular events in all patients with ischemic heart disease treated with an ACE inhibitor 
even in the absence of systolic left ventricular dysfunction or evidence of heart failure. 
These unique findings of these landmark trials are herein discussed.
I N T R O D U C T I O N
Although the medical treatment of ischemic heart disease (IHD) over the past 
25 years has evolved based on randomized clinical trials to include aspirin, nitrates, 
beta-blockers, angiotensin II-receptor blockers, aldosterone-blockers and revascu-
larization therapies; a very significant addition to this regimen for both primary and 
secondary prevention of IHD has been the understanding of angiotensin-converting 
enzyme (ACE) inhibitors. Introduced in the 1980s as an anti-hypertensive therapy,1 
the benefit of ACE-inhibitors in heart failure, acute myocardial infarction, remodeling 
of left ventricular mass, reno-protection independent of blood pressure lowering, 
reduction of lipids, and reducing the risk of myocardial infarction, stroke, sudden 
death, cardiovascular death and new onset diabetes has been established by numerous 
randomized, double-blind, placebo-controlled clinical trials. This brief report focuses 
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on the unique aspects realized from the Heart Outcomes 
Prevention Evaluation (HOPE),2 the EURopean trial On 
reduction of cardiac events with Perindopril in stable coronary 
Artery disease (EUROPA),3 and the Prevention of Events with 
Angiotensin Converting Enzyme Inhibition (PEACE)4 Trials 
and their combined analysis.5
P R E v I O U S  A C E - I N h I B I T O R  T R I A l S
When originally introduced clinically, ACE-inhibitors 
were considered as adjunctive therapy to treat hypertensive 
patients suspected of high angiotensin levels.1 In the most 
recent application of ACE-inhibitors to a hypertensive popu-
lation of 10,985 patients in the Captopril Prevention Project 
(CAPPP),6 captopril failed to demonstrate superiority over 
a conventional beta-blocker/diuretic regimen in reducing 
cardiovascular events. Notwithstanding that outcome, the 
realization that some ACE-inhibitors possess tissue effects 
that are beneficial on left ventricular structure and function 
even in patients with controlled blood pressure and preserved 
ejection fraction, argues for primary and secondary preventive 
benefit in a wide range of hypertensive patients. Following 
introduction clinically, the application of ACE-inhibitors 
in patients with symptomatic heart failure in the Veterans 
Administration Cooperative Vasodilator-Heart Failure 
Trial (V-HeFT I),8 the Cooperative North Scandinavian 
Enalapril Survival Study (CONSENSUS),9 the Study of Left 
Ventricular Dysfunction (SOLVD),10 and V-HeFT II11 clearly 
established ACE-inhibitors as a cornerstone of therapy in 
patients with systolic heart failure. During these trials other 
important observations were appreciated. ACE-inhibitors 
were demonstrated both experimentally and during clinical 
trials to improve renal insufficiency, retard the progression of 
renal disease, and improve nephropathies in both diabetics 
and non-diabetics.12 Simultaneously, both experimental and 
clinical data demonstrated that ACE-inhibitors attenuated 
the adverse remodeling that accompanied acute myocardial 
infarction,13,14 and provided the original stimulus to employ 
ACE-inhibitors in acute myocardial infarction. Subsequently, 
ACE-inhibitors were employed early in the course of acute 
myocardial infarction in SAVE,14 the Acute Infarction Rami-
pril Efficacy (AIRE),15 the Gruppo Italianao per la Studio 
della Sopravvivienza nell’Infarcto Miocardico (GISSI)-316 
and the Fourth International Study of Infarct Survival 
(ISIS-4)1 trials and clearly established their benefit in the 
secondary prevention of mortality, cardiovascular mortality, 
re-infarction and fatal myocardial infarction. Overall, there 
was a consistent reduction of mortality and cardiovascular 
mortality during the acute and chronic phases of myocardial 
infarction and chronic ischemic heart disease. The most 
impressive results were demonstrated in high-risk patients 
who maintained ACE-inhibitor therapy chronically. These 
factors unequivocally made ACE-inhibitors the foundation of 
anti-ischemic secondary preventive therapy for both short and 
long-term benefit in systolic heart failure,18 and an important 
anti-ischemic therapy in ischemic heart disease, diabetic and 
renal disease patients.
T h E  h O P E  T R I A l
As a result of the SAVE14 and SOLVD10 trials, the benefit 
of ACE-inhibitors in preventing reinfarction and ischemia 
stimulated new investigations into mechanisms of how the 
renin-angiotensin-aldosterone system could be interacting in 
the emerging discoveries of endothelial dysfunction associated 
with atherosclerosis. Although hypertension and heart failure 
had become major therapeutic targets for ACE-inhibitors, by 
the 1990s it had become eminently clear that ACE-inhibitors 
were affecting vascular tissue in a beneficial way in many 
disease populations.
Thus the HOPE2 trial explored this possibility by testing 
the hypothesis that ACE-inhibitors could favorably prevent 
atherosclerotic cardiovascular events. The HOPE trial selected 
929 men and women older than 55 years of age at increased 
risk of cardiovascular disease, defined as a history of a cardio-
vascular event or evidence of vascular disease (angina, periph-
eral vascular disease or stroke). Persons with diabetes mellitus 
but no indication of heart disease were included but had to 
have an additional risk factor. Important exclusions were heart 
failure, a decreased ejection fraction <0.40, prior use of an 
ACE-inhibitor and renal insufficiency.2 The study enrolled 
patients from 19 countries in a two-by-two factorial design for 
randomization to either the ACE-inhibitor ramipril 10 mg dai-
ly, vitamin E 400 IU daily or placebo and were followed for a 
mean of 5 years. Whereas no beneficial effects of vitamin E on 
cardiovascular outcomes were disclosed,1 there was a marked 
effect of ramipril on the primary endpoint, a 22% reduction 
in a composite measure of myocardial infarction, stroke and 
death from cardiovascular causes and significant reductions on 
each individual endpoint.2 Significantly decreased mortality 
or morbidity was also observed for all-cause mortality (16%), 
revascularization (15%), heart failure (23%), cardiac arrest 
(3%), worsening angina (11%) and complications related 
to diabetes (16%).2 These findings established that ramipril 
would benefit a broad range of patients for both primary and 
secondary prevention of both ischemic and vascular disease, 
and was beneficial in all subgroups of atherosclerotic coronary 
disease, cerebrovascular disease, peripheral vascular disease, 
or diabetes with one cardiovascular risk factor.2 Benefits were 
observed whether or not patients were also taking aspirin, 
other antiplatelet agents, beta-blockers, lipid-lowering agents, 
or other antihypertensive drugs at randomization. Treating 
1000 patients with ramipril for four years prevented 150 
events in 0 patients.2
Following publication of the HOPE trial there emerged 
several substudies indicating that ramipril reduced progres-
sion on atherosclerosis and improved myocardial remodeling. 
Although an early debate emerged that the benefits of ramipril 
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might have resulted from its modest blood pressure lowering 
(3/2 mmHg) effects,2 the emergence of these data made it 
clear that the effects on the vasculature, heart, and kidneys 
went far beyond these small effects. One of the early reports20 
from the HOPE study of 35 diabetics showed the primary 
endpoint to be lowered by 25%, myocardial infarction by 
22%, stroke by 33% and cardiovascular death by 3%. The 
Microalbuminuria, Cardiovascular and Renal Outcomes in 
HOPE (MICRO-HOPE) study20 showed that ramipril lowered 
the risk of overt nephropathy in participants who did and 
did not have baseline microalbuminuria, and led to a lower 
albumin/creatinine ratio than placebo at 1 year and at the end 
of the study. There was a 34% reduction in new diagnoses of 
diabetes.2 When the substudy data of 2480 high-risk women 
≤55 years of age in HOPE were examined, the beneficial ef-
fects of ramipril were found to be similar to those detected in 
the larger cohort of men.21 Further examination of the effects 
of ramipril disclosed that while the relative risk of any stroke 
was reduced by 32% (ramipril 156 vs placebo 226), the relative 
risk of fatal stroke was reduced by 61% (ramipril 1 vs placebo 
44).22 Significantly fewer patients on ramipril had cognitive or 
functional impairment.22 Echocardiographic measurements 
of a HOPE subgroup that received two doses of ramipril (10 
mg/d vs 2.5 mg/d) versus placebo in 506 patients with vascular 
disease on measurements of left ventricular mass and left 
ventricular function, showed beneficial remodeling in the 
ramipril treated patients.23 The greatest benefit was found in 
the patients receiving ramipril 10 mg/d.23 More recently HOPE 
substudy data have defined that there were trends over the 
median follow-up of 4.5 years that showed reduction in fatal 
primary outcome events (unexpected death or documented 
arrhythmic death; relative risk-RR 0.81, P=0.02) and nonfa-
tal primary outcome events (resuscitated cardiac arrest; RR 
0.65, P=0.12).24 These observations are more germane when 
it is realized that these arrhythmic benefits were rendered in 
the absence of clinical heart failure or left ventricular systolic 
dysfunction. Similarly, another recent substudy23 of HOPE in 
3099 patients with a subnormal (≤0.9) ankle-brachial index 
(ABI) showed the ABI to be a strong predictor of mortality 
and morbidity during the follow-up even in patients with no 
clinical symptoms of peripheral arterial disease. Ramipril 
reduced the primary outcome of the study and all-cause mor-
tality.25 Whereas the HOPE trial measured the ABI employing 
digital palpation of ankle pulse as a relatively crude index, the 
data show that this simple measurement identified a high-risk 
subgroup that ramipril prevented events even in the absence 
of clinical symptoms of peripheral arterial disease.
These factors would be expected to influence all physicians 
to cast a wider perspective of the benefits of the ACE-inhibi-
tor ramipril, and to prescribe it on a wider basis. In a study26 
of prescriptions filled in Ontario, Canada, from 1993 to 2001 
there was an observed striking increase of 400% in ramipril 
prescription to elderly Ontario residents, including those 
not eligible for the trial. Whereas the fact that HOPE was a 
Canadian-led trial which undoubtedly had some influence 
on those observations, nevertheless is a dramatic testament 
to physician’s acceptance of the HOPE data.
T h E  E U R O PA  T R I A l
Following the publication of the HOPE trial, previous 
and evolving studies of ACE-inhibitors suggested that there 
were distinct properties associated with ramipril. Quantitative 
differences exist between ACE-inhibitors, and because of the 
highly lipophilic and strong enzyme-binding capability associ-
ated with ramipril, this “tissue” ACE-inhibition feature drew 
attention. Perindopril is an ACE-inhibitor that also has these 
properties. Accordingly the EUROPA investigators sought to 
test whether perindopril could prevent atherosclerotic events 
in a low-risk population with stable coronary heart disease and 
no apparent heart failure.3 Patients recruited had to be at least 
18 years of age, and have evidence of coronary heart disease 
without clinical evidence of heart failure. Exclusion criteria 
included evidence of heart failure, uncontrolled hypertension, 
hypotension, renal insufficiency and recent use of ACE-in-
hibitors.3 A total of 13,655 patients were recruited with either 
previous myocardial infarction (64%), angiographic evidence 
of coronary artery disease (61%), coronary revascularisation 
(55%), or a positive stress test only (5%). After a run-in period 
of 4 weeks, in which all patients received perindopril, 12218 
patients were randomly assigned perindopril 8 mg once daily 
(n=6110) or matching placebo (n=6108). The mean follow-up 
was 4.2 years, and the primary endpoint was cardiovascular 
death, myocardial infarction, or cardiac arrest. Benefit was 
observed approximately after 1.5 years of treatment, and 
the event curves continued to separate being significant at 3 
years and thereafter. This benefit showed a 20% relative risk 
reduction with perindopril over 4.2 years, and was consistently 
present in all predefined subgroups and secondary endpoints.3 
Approximately 50 patients needed to be treated for 4 years to 
prevent one major cardiovascular event.
In contrast to HOPE, EUROPA examined a relatively low-
risk (placebo mortality 12% vs % over 4 years duration) group 
of patients of younger age (mean age 66 vs 60 years). The major 
annual event rates in HOPE were 40% to 80% higher than in 
EUROPA.3 The frequency of clinical myocardial infarction 
and cardiovascular death was reduced by 21% in HOPE, and 
a similar 20% reduction was noted in EUROPA.2,3 This is all 
the more surprising when it is realized that a higher usage of 
beneficial concomitant medications were taken in EUROPA, 
i.e. platelet inhibitors 92%, beta-blockers 62% and lipid-
lowering therapy 58%. Thus, the benefit of perindopril was 
evident on top of current recommended secondary preventive 
therapies. Once again there was controversy over a lowering 
of blood pressure (5/2 mm Hg) as the mechanism for perin-
dopril’s benefit, nonetheless proponents of the study indicate 
this change did not account in EUROPA’s low-risk group for 
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such an effect.2 Therefore, the EUROPA trial complemented 
the findings of the HOPE trial in indicating the unique ability 
of tissue ACE-inhibition in preventing atherosclerotic car-
diovascular events. These observations appear to be true for 
both low and high-risk individuals without evidence of heart 
failure or left ventricular dysfunction, and in the presence of 
concomitant secondary preventive therapies of platelet inhibi-
tion, beta-blocker therapy and lipid-lowering agents.
As of the present, substudies of EUROPA have not been 
published, and are awaited with regards to various subgroups 
of this low-risk population.
T h E  P E A C E  T R I A l
The PEACE trial is the latest randomized trial testing an 
ACE inhibitor in IHD patients with normal or near-normal 
systolic left ventricular function (mean ejection fraction 
58±9%).4 It comprised 8290 patients, randomly assigned to 
either trandolapril (4158 patients) or placebo (4132 patients). 
Patients received optimal therapy, with 2% having had 
coronary revascularization and 0% receiving lipid-lowering 
drugs. The incidence of the primary end point — death from 
cardiovascular causes, myocardial infarction, or coronary 
revascularization — was 21.9% in the trandolapril group, and 
22.5% in the placebo group (P=0.43) over a median follow-
up period of 4.8 years. Thus, trandolapril was not effective in 
the PEACE Trial, which apparently recruited patients with a 
lower cardiovascular risk compared with the prior two trials, as 
patients in PEACE received more intensive therapy, including 
coronary revascularization and lipid-lowering agents.
C O M B I N E D  A N A l y S I S
A combined analysis of all three trials (HOPE, EUROPA, 
and PEACE trials including 29,805 patients)5 indicated that 
ACE inhibitors significantly reduced all-cause mortality 
(.8 vs 8.9%, p=0.0004), cardiovascular mortality (4.3 vs 
5.2%, p=0.0002), non-fatal myocardial infarction (5.3 vs 
6.4%, p=0.0001), all stroke (2.2 vs 2.8%, p=0.0004), heart 
failure (2.1 vs 2.%, p=0.000), and coronary-artery bypass 
surgery (6.0 vs 6.9%, p=0.0036). The composite end-point 
(cardiovascular mortality, non-fatal myocardial infarction, 
or stroke) occurred in 1599 (10.%) of the patients receiving 
ACE inhibitor and in 1910 (12.8%) of those in the placebo 
group (odds ratio, 0.82; p<0.0001).
Thus, ACE inhibitors appear to reduce vascular events 
in patients with IHD even without known evidence of systolic 
dysfunction or heart failure and their use should at least be 
considered in all patients with IHD.
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